Antiretrovirals and safer conception for HIV-serodiscordant couples

Current Opinion in HIV and AIDS

Volumn 7, Issue 6, 2012, Pages 569-578

  Matthews, Lynn T ^a   Smit, Jennifer A ^b   Cu Uvin, Susan ^c   Cohan, Deborah ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antiretrovirals as prevention; conception; fertility; HIV prevention; HIV serodiscordance; perinatal HIV transmission; sexual HIV transmission

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PLACEBO; TENOFOVIR DISOPROXIL; VIRUS RNA;

ANTIVIRAL THERAPY; CHEMOPROPHYLAXIS; CONCEPTION; DRUG EFFICACY; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PATIENT COMPLIANCE; PREEXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CHEMOPREVENTION; DISEASE TRANSMISSION, INFECTIOUS; FAMILY CHARACTERISTICS; FEMALE; FERTILIZATION; HIV INFECTIONS; HUMANS; MALE; SEXUAL PARTNERS;

EID: 84868499863     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328358bac9     Document Type: Review

References (122)

1. Chen JL, Philips KA, Kanouse DE, et al. Fertility desires and intentions of HIV-positive men and women. Fam Plann Perspect 2001; 33:144- 152.
2. Ogilvie GS, Palepu A, Remple VP, et al. Fertility intentions of women of reproductive age living with HIV in British Columbia, Canada. AIDS 2007; 21 (Suppl 1):S83-S88.
3. Frodsham LC, Boag F, Barton S, Gilling-Smith C. Human immunodeficiency virus infection and fertility care in the United Kingdom: demand and supply. Fertil Steril 2006; 85:285-289.
4. Heard I, Sitta R, Lert F. Reproductive choice in men and women living with HIV: evidence from a large representative sample of outpatients attending French hospitals (ANRS-EN12-VESPA Study). AIDS 2007; 21 (Suppl 1): S77-S82.
5. Panozzo L, Battegay M, Friedl A, Vernazza PL. High risk behaviour and fertility desires among heterosexual HIV-positive patients with a serodiscordant partner-two challenging issues. Swiss Med Wkly 2003; 133:124-127.
6. Beyeza-Kashesya J, Ekstrom AM, Kaharuza F, et al. My partner wants a child: a cross-sectional study of the determinants of the desire for children among mutually disclosed sero-discordant couples receiving care in Uganda. BMC Public Health 2010; 10:247.
7. Cooper D, Moodley J, Zweigenthal V, et al. Fertility intentions and reproductive healthcare needs of people living with HIV in Cape Town, South Africa: implications for integrating reproductive health and HIV care services. AIDS Behav 2009; 13 (Suppl 1):38-46.
8. Homsy J, Bunnell R, Moore D, et al. Reproductive intentions and outcomes among women on antiretroviral therapy in rural Uganda: a prospective cohort study. PLoS ONE 2009; 4:e4149.
9. Myer L, Morroni C, Rebe K. Prevalence and determinants of fertility intentions of HIV-infected women and men receiving antiretroviral therapy in South Africa. AIDS Patient Care STDS 2007; 21:278-285.
10. Nakayiwa S, Abang B, Packel L, et al. Desire for children and pregnancy risk behavior among HIV-infected men and women in Uganda. AIDS Behav 2006; 10 (4 Suppl):S95-S104.
11. Preston-Whyte E. Culture, context and behaviour: anthropological perspectives on fertility in Southern Africa. South Afr J Demogr 1988; 2:13-23.
12. Beyeza-Kashesya J, Kaharuza F, Mirembe F, et al. The dilemma of safe sex and having children: challenges facing HIV sero-discordant couples in Uganda. African Health Sci 2009; 9:2-12.
13. Cooper D, Harries J, Myer L, et al. 'Life is still going on': reproductive intentions among HIV-positive women and men in South Africa. Soc Sci Med 2007; 65:274-283.
14. Dunkle KL, Stephenson R, Karita E, et al. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet 2008; 371:2183-2191.
15. Guthrie BL, de Bruyn G, Farquhar C. HIV-1-discordant couples in sub- Saharan Africa: explanations and implications for high rates of discordancy. Curr HIV Res 2007; 5:416-429.
16. Eyawo O, de Walque D, Ford N, et al. HIV status in discordant couples in sub- Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:770-777.
17. Mantell JE, Smit JA, Stein ZA. The right to choose parenthood among HIVinfected men and women. J Public Health Policy 2009; 30:367-378.
18. Gruskin S, Ferguson L, O'Malley J. Ensuring sexual and reproductive health for people living with HIV: an overview of key human rights, policy and health systems issues. Reprod Health Matters 2007; 15 (Suppl 29):4-26.
19. London L, Orner PJ, Myer L. 'Even if you're positive, you still have rights because you are a person': human rights and the reproductive choice of HIVpositive persons. Dev World Bioeth 2008; 8:11-22.
20. GNP, ICW, Young Positives, EngenderHealth, IPPF, and UNAIDS, Advancing the sexual and reproductive health and human rights of people living with HIV: a guidance package, 2009, The Global Network of People Living with HIV/AIDS: Amsterdam.
21. World Health Organization, Guidance on couples HIV testing and counselling including antiretroviral therapy for treatment and prevention in serodiscordant couples, 2012: Geneva.
22. Matthews LT, Crankshaw T, Giddy J, et al. Reproductive decision-making and periconception practices among HIV-positive men and women attending HIV services in Durban, South Africa. AIDS Behav, 2011 [Epub ahead of print].
23. Harris C, Small CB, Klein RS, et al. Immunodeficiency in female sexual partners of men with the acquired immunodeficiency syndrome. N Engl J Med 1983; 308:1181-1184.
24. Piot P, Quinn TC, Taelman H, et al. Acquired immunodeficiency syndrome in a heterosexual population in Zaire. Lancet 1984; 2:65-69.
25. Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.
26. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643-656.
27. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657-666.
28. Eke AC, Oragwu C. Sperm washing to prevent HIV transmission from HIVinfected men but allowing conception in sero-discordant couples. Cochrane Database Syst Rev 2011(1):CD008498.
29. Bujan L, Hollander L, Coudert M, et al. Safety and efficacy of sperm washing in HIV-1-serodiscordant couples where the male is infected: results from the European CREAThE network. AIDS 2007; 21:1909-1914.
30. Savasi V, Ferrazzi E, Lanzani C, et al. Safety of sperm washing and ART outcome in 741 HIV-1-serodiscordant couples. Hum Reprod 2007; 22: 772-777.
31. Vitorino RL, Grinsztejn BG, de Andrade CA, et al. Systematic review of the effectiveness and safety of assisted reproduction techniques in couples serodiscordant for human immunodeficiency virus where the man is positive. Fertil Steril 2011; 95:1684-1690.
32. de Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med 1994; 331:341-346.
33. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002(1):CD003255.
34. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med 2011; 365:493-505.
35. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-2098.
36. Attia S, Egger M, Muller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404.
37. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV-1 prevention in heterosexual men and women. NEJM 2012; 367:399-410.
38. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. NEJM 2012; 367:423-434
39. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. NEJM 2012; 367:411-422.
40. Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346:530-536.
41. Wawer MJ, Gray RH, Sewankambo NK, et al. A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda. AIDS 1998; 12:1211-1225.
42. Philips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M. Oxford Centre for Evidence-based Medicine - Levels of Evidence. March 2009; http://www.cebm.net/index.aspx. [Accessed on 30 May 2012].
43. Mmeje O, Cohen C, Cohan D. Evaluating safer conception options for HIV-infected female/HIV-uninfected male serodiscordant couples: a closer look at vaginal insemination. Infect Dis Obstet Gynecol 2012; 206:e21.
44. Semprini AE, Levi-Setti P, Bozzo M, et al. Insemination of HIV-negative women with processed semen of HIV-positive partners. Lancet 1992; 340:1317-1319.
45. Politch JA, Anderson DJ. Use of assisted reproductive technology to prevent the transmission of HIV-1 in HIV-discordant couples desiring children. Immunol Allergy Clin North America 2002; 22:663-679.
46. Sauer MV, Wang JG, Douglas NC, et al. Providing fertility care to men seropositive for human immunodeficiency virus: reviewing 10 years of experience and 420 consecutive cycles of in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril 2009; 91:2455-2460.
47. Nicopoullos JD, Almeida P, Vourliotis M, Gilling-Smith C. A decade of the United Kingdom sperm-washing program: untangling the transatlantic divide. Fertil Steril 2010; 94:2458-2461.
48. Lampe MA, Smith DK, Anderson GJ, et al. Achieving safe conception in HIVdiscordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol 2011; 204:488.e1-8.
49. Barreiro P, del Romero J, Leal M, et al. Natural pregnancies in HIVserodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43:324-326.
50. Mandelbrot L, Heard I, Henrion-Geant E, Henrion R. Natural conception in HIV-negative women with HIV-infected partners. Lancet 1997; 349:850- 851.
51. Matthews L, Mukherjee J. Strategies for harm reduction among HIV-affected couples who want to conceive. AIDS and Behavior 2009; 13 (Suppl 1): S5-S11.
52. Crankshaw T, Matthews LT, Giddy J, et al. A conceptual framework for periconception HIV transmission risk reduction among HIV serodiscordant couples. Reprod Health Matters 2012(in press).
53. Jewkes R, Morrell R. Gender and sexuality: emerging perspectives from the heterosexual epidemic in South Africa and implications for HIV risk and prevention. J Int AIDS Soc 2010; 13:6.
54. Kelley AL, Karita E, Sullivan PS, et al. Knowledge and perceptions of couples' voluntary counseling and testing in urban Rwanda and Zambia: a crosssectional household survey. PLoS ONE 2011; 6:e19573.
55. UNAIDS, Fact Sheet: Women, girls, gender equality, and HIV 2010, UNAIDS. http://www.data.unaids.org/pub/FactSheet/2010/20100302-fs- womenhiv- en.pdf. [Accessed 30 May 2012].
56. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
57. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-1409.
58. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE 2010; 5:e11068.
59. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-539.
60. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
61. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
62. Microbicide Trials Network. MTN statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women 2011.http://www.mtnstopshiv.org/node/3619. [Accessed on 28 September 2011].
63. Microbicide Trials Network. MTN statement on decision to discontinue use of Tenofovir gel in VOICE, a major HIV prevention study in women 2011http://www.mtnstopshiv.org/node/3909. [Accessed on 25 November 2011].
64. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of preexposure prophylaxis trials for HIV prevention. AIDS 2012; 26:F13-F19.
65. Ware NC, Wyatt MA, Haberer JE, et al. What's love got to do with it? Explaining adherence to oral antiretroviral preexposure prophylaxis for HIVserodiscordant couples. J Acquir Immune Defic Syndr 2012; 59:463- 468.
66. Press release: FDA approves first drug for reducing the risk of sexually acquired HIV infection2012. www.fda.gov. [Accessed on 16 July 2012].
67. Vernazza PL, Graf I, Sonnenberg-Schwan U, et al. Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child. AIDS 2011; 25:2005-2008.
68. Bekker LG, Black V, Myer L, et al. Guideline on safer conception in fertile HIV-infected individuals and couples. Southern African J HIV Med 2011; 12:31-44.
69. Mocroft A, Miller V, Chiesi A, et al. Virological failure among patients on HAART from across Europe: results from the EuroSIDA study. Antivir Ther 2000; 5:107-112.
70. Cescon AM, Cooper C, Chan K, et al. Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multisite Canadian cohort. HIV Med 2011; 12:352-360.
71. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002; 16:53-61.
72. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
73. World Health Organization, Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision, 2010, W.H.O.: Geneva.
74. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services, 2012. http://aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. [Accessed on 1 May 2012].
75. Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre and postexposure prophylaxis. AIDS 2007; 21:1899-1907.
76. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re4.
77. Mutua G, Sanders E, Mugo P, et al. Safety and adherence to intermittent preexposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS ONE 2012; 7:e33103.
78. Wilcox AJ, Baird DD, Dunson D, et al. Natural limits of pregnancy testing in relation to the expected menstrual period. JAMA 2001; 286:1759-1761.
79. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2- phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265-4273.
80. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995; 270:1197- 1199.
81. Cong ME, Youngpairoj AS, Zheng Q, et al. Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada. J Virol 2011; 85:7933-7936.
82. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008; 5:e28.
83. Mugo N, Celum C, Donnell D, et al. Pregnancy Incidence and Birth Outcomes among in a Clinical Trial of PrEP: Uganda and Kenya. CROI 2012: Seattle. #1060.
84. Mugo NR, Heffron R, Donnell D, et al. Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1-serodiscordant couples. AIDS 2011; 25:1887-1895.
85. Kharsany AB, Hancock N, Frohlich JA, et al. Screening for 'window-period' acute HIV infection among pregnant women in rural South Africa. HIV Med 2010; 11:661-665.
86. Moodley D, Esterhuizen TM, Pather T, et al. High HIV incidence during pregnancy: compelling reason for repeat HIV testing. AIDS 2009; 23:1255- 1259.
87. The Antiretroviral Pregnancy Registry, apregistry.com, [Accessed on 15 May 2012].
88. Black V, Brooke S, Chersich MF. Effect of human immunodeficiency virus treatment on maternal mortality at a tertiary center in South Africa: a 5-year audit. Obstet Gynecol 2009; 114 (2 Pt 1):292-299.
89. Hogan MC, Foreman KJ, Naghavi M, et al. Maternal mortality for 181 countries, 1980-2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet 2010; 375:1609-1623.
90. WHO, Programmatic Update: Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Executive summary, 2012.Geneva.
91. WHO, Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: Recommendations for a public health approach, 2010, WHO: Geneva.
92. Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission, Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States, 2011. 1-207. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf. [Accessed on 1 May 2012].
93. Tubiana R, Le Chenadec J, Rouzioux C, et al. Factors associated with motherto- child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPFANRS CO1). Clin Infect Dis 2010; 50:585-596.
94. Read PJ, Mandalia S, Khan P, et al. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS 2012; 26:1095-1103.
95. Matthews LT, Baeten JM, Celum C, Bangsberg DR. Periconception preexposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS 2010; 24:1975-1982.
96. Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3:77ra29.
97. Marcelin AG, Tubiana R, Lambert-Niclot S, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma. AIDS 2008; 22:1677-1679.
98. Lambert-Niclot S, Tubiana R, Beaudoux C, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey. AIDS 2012; 26:971-975.
99. Cu-Uvin S, Caliendo AM. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2011; 25:880-881.
100. Launay O, Tod M, Tschope I, et al. Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study. Antivir Ther 2011; 16:843- 852.
101. Lambert-Niclot S, Peytavin G, Duvivier C, et al. Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapy. Antimicrob Agents Chemother 2010; 54:4910-4913.
102. Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral preexposure prophylaxis: implications for HIV prevention in women. Lancet 2011; 378:279-281.
103. Brown KC, Patterson KB, Malone SA, et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis 2011; 203:1484-1490.
104. Cohen MS, Muessig KE, Smith MK, et al. Antiviral agents and HIV prevention: controversies, conflicts and consensus. AIDS 2012; 26:1585-1598.
105. Nielsen-Saines K, Komarow L, Cu-Uvin S, et al. Infant outcomes after maternal antiretroviral exposure in resource-limited settings. Pediatrics 2012; 129:e1525-e1532.
106. Culnane M, Fowler M, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999; 281:151-157.
107. Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17:1769-1785.
108. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354:1084-1089.
109. Howard AA, Arnsten JH, Lo Y, et al. A prospective study of adherence and viral load in a large multicenter cohort of HIV-infected women. AIDS 2002; 16:2175-2182.
110. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-366.
111. Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009; 50:529-536.
112. Donnell D, Baeten JM, Hendrix C, et al. Tenofovir disoproxil fumarate drug-levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda. CROI 2012: Seattle. (abstract no. 30).
113. Mindry D, Maman S, Chirowodza A, et al. Looking to the future: South African men and women negotiating HIV risk and relationship intimacy. Cult Health Sex 2011; 13:589-602.
114. Bardeguez AD, Lindsey JC, Shannon M, et al. Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr 2008; 48:408-417.
115. Sha BE, Tierney C, Cohn SE, et al. Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150. HIV Clin Trials 2011; 12: 9-23.
116. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011; 8:e1001123.
117. Walensky RP, Park JE, Wood R, et al. The cost-effectiveness of preexposure prophylaxis for HIV infection in South African women. Clin Infect Dis 2012; 54:1504-1513.
118. Granich R, Kahn JG, Bennett R, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS ONE 2012; 7:e30216.
119. Schwartz SR, Mehta SH, Taha TE, et al. High pregnancy intentions and missed opportunities for patient-provider communication about fertility in a south African cohort of HIV-positive women on antiretroviral therapy. AIDS Behav 2012; 16:69-78.
120. Finocchario-Kessler S, Dariotis JK, Sweat MD, et al. Do HIV-infected women want to discuss reproductive plans with providers, and are those conversations occurring? AIDS Patient Care STDS 2010; 24:317-323.
121. Gogna ML, Pecheny MM, Ibarlucia I, et al. The reproductive needs and rights of people living with HIV in Argentina: health service users' and providers' perspectives. Soc Sci Med 2009; 69:813-820.
122. Harries J, Cooper D, Myer L, et al. Policy maker and healthcare provider perspectives on reproductive decision-making amongst HIVinfected individuals in South Africa. BMC Public Health 2007; 7:282.